Pure Biologics, Twist partner on immuno-oncology drugs

By The Science Advisory Board staff writers

Pure Biologics and Twist Bioscience have partnered to accelerate the discovery of antibody-based immuno-oncology drugs.

Under the agreement, Twist Biopharma, a division of Twist Bioscience, will grant access to Pure Biologics to select synthetic antibody phage display libraries derived from sequences that exist only in the human body and that are optimized using artificial intelligence and big data analytics.

The companies will work together to develop new antibody candidates that are useful for immuno-oncology therapies. Certain libraries are tailored deliberately to match chosen classes of biological targets.

Pure Biologics will pay Twist technology access fees annually, as well as future payments for preclinical, clinical, and commercial achievement for any antibodies resulting from the deal.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?